Revolution Medicines Inc.’s KRAS inhibitor, Rasonque (daraxonrasib), received a thumbs-up from the EMA’s Committee for ...

Estuary Biotherapeutics Inc. emerged from stealth with a $93 million series A financing led by RA Capital Management to develop gene therapies to treat autosomal dominant polycystic kidney disease ...

Life sciences investors are raising billions of dollars in fresh capital, with a cluster of new funds and acquisition vehicles positioning specialist firms for more biotech company formation and ...

About two years after launching, RNAi-focused City Therapeutics Inc., a company co-founded by former Alnylam Pharmaceuticals Inc. founder and CEO John Maraganore, raised $200 million through an IPO to ...

Biopharma deals, excluding M&As, reached $224.91 billion in the first nine months of 2026, up 5% from $213.62 billion during the same period in 2025. The year-to-date total was the highest in BioWorld ...

A consortium funded by the National Institutes of Health (NIH) has unveiled the most comprehensive map of somatic mosaicism ...

Following ongoing deals with Bristol Myers Squibb Co. and Eli Lilly and Co., AI and machine learning firm Insitro Inc. has ...

An observational study of 70,257 U.S. patients with both schizophrenia and type 2 diabetes has added weight to the emerging ...

Just in time for the flu season, Sanofi SA has reached an agreement to resolve the EU Commission’s preliminary concerns about ...

The U.S. FDA accepted Zydus Lifesciences Ltd. and Formycon AG’s BLA for FYB-206, a proposed biosimilar to Keytruda ...

Omass Therapeutics Ltd. has raised £230 million (US$305 million) in a series C after transitioning to a clinical-stage company, and is now funded to take the lead program through phase II and move a ...